Through Bionut, a leader in obesity care in Argentina, Allurion Program patients will now have access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule
Strong quarter-over-quarter revenue growth with continued, substantial improvement in operating expenses and operating loss
Average Total Weight Loss of 23% With 14% Increase in Lean Body Mass After 12 Months All patients remained adherent to tirzepatide for the duration of the study
Case-controlled study in 1,143 patients demonstrates superior weight reduction, fat mass loss, and visceral fat loss with the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle...
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with ProSurg Medical, a leading Brazilian medical device company...
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update. ...
Passing of key audits with zero findings and completion of Day-100 meeting are significant milestones in the FDA PMA process as the Company enters final stages of FDA review process for its Allurion Smart...
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the third quarter...
Multicenter study across six countries demonstrates safety and efficacy of two consecutive treatments in adults with obesity Weight loss of greater than 20% on par with...
Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its participation in the ROTH 4 th Annual Healthcare Opportunities Conference, which...